Actym Therapeutics
Recent Finacing
Series A
Recent Raise
$25.5M
Actym Therapeutics develops a new drug modality using genetically modified bacteria to initiate a selective immune response within the tumor microenvironment for treating solid tumors.
Focus Areas
cancer treatment
solid tumors
drug modality
Investors
